Search

Home

The European Hematology Association promotes excellence in patient care, research, and education in hematology. We serve medical professionals, researchers, and scientists with an active interest in hematology.

Read more

EHA Exam

An annual assessment designed to test your knowledge of the European Hematology Curriculum. EHA Exam 2025
The 9th European Hematology Exam will take place on June 12, 2025, from 13:30–16:00 (CEST).

Read more

EHA-SWG Scientific Meeting on Immunotherapy for Hematological Disorders

EHA and the Scientific Working Group on Immunotherapy for Hematological Disorders are happy to announce the redesigned fully virtual meeting program to meet the needs of hematologists and immunologists in these challenging times.

Read more

Highlights from the SWG

Events
The ERIC International Preceptorship, Realizing Precision Medicine in CLL: Why and How
Stresa, Italy
November 17–18, 2023
PublicationsRecent ERIC publications include:

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia
Other malignancies in the history of CLL: an international multicenter study conducted…

Read more

A European Reference Network for Rare Hematological Diseases

You may have heard of European Reference Networks (ERNs). But most likely you have not. ERNs are networks of specialized hospital departments and research centers to treat rare or low-prevalent complex diseases.

Read more

For mentors of applicants

As part of your support for the candidate applying for CBTH, the following is required from you:

Supervision and mentorship to be provided to the applicant during the CBTH award year.

Read more

Board

The EHA Board is the governing body of the association and deals with issues of policy. The Board sets the goals and objectives of the association in conformity with the EHA's statutes.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

Healthcare-affiliated professional membership

You don't need to be scientific researcher or a physician to join our vibrant community.

Read more